The benefits of GLP-1 drugs beyond obesity

Science. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128. Epub 2024 Jul 18.

Author

Daniel J Drucker¹

Affiliation

¹ The Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

PMID: 39024455
DOI: 10.1126/science.adn4128

Abstract

Glucagon-like peptide-1-based medicines have weight loss-independent actions.

MeSH terms

Animals
Cardiovascular System* / drug effects
Diabetes Mellitus, Type 2 / drug therapy
Glucagon-Like Peptide 1* / administration & dosage
Glucagon-Like Peptide 1* / pharmacology
Glucagon-Like Peptide-1 Receptor Agonists / administration & dosage
Glucagon-Like Peptide-1 Receptor Agonists / pharmacology
Glucagon-Like Peptides* / administration & dosage
Glucagon-Like Peptides* / pharmacology
Humans
Liraglutide / administration & dosage
Liraglutide / pharmacology
Myocardial Ischemia / prevention & control
Myocardial Ischemia / therapy
Semaglutide
Weight Loss* / drug effects

Substances

Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptides
Liraglutide
Semaglutide